Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Shareholder Meeting (November 2016)
19 slides from Neurizon Therapeutics's shareholder meeting presentation, November 2016
Slide 1: Investor Presentation AGM 2016
For personal use only ASX: PAA Investor Presentation ACN 094 006 023 AGM 2016 November 2016
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the Co pa y . It does not purport to contain all the For personal use only information that a prospective investor may require in connection with any potential investment in the Company. You
Slide 3: Financial Snapshot
Financial Snapshot For personal use only 1. Ex Price $0.16, Expiry Date 3 September 2018 ASX: PAA
Slide 4: Business Overview
Business Overview Proprietary • MPL Approved for Vet (Novartis Animal Health) For personal use only Technology • Patents for use in cancer PharmAust Option with Novartis • Efficacy in Canine Cancer -> Option Exercise Animal Health Epichem Contract • 2016 - $2.4M Sales • 2017 - $3.0M Phase II Canine
Slide 5: Key Drivers for 2017
Key Drivers for 2017 For personal use only Phase II Outcome (Canine) Option Exercise by Novartis-Elanco NASDAQ Listing and Capital Raise Initiation Phase II (MAN) Growth of Epichem Business ASX: PAA 5
Slide 6: Performance of MPL in Canines (Phase II)
Performance of MPL in Canines (Phase II (CANINES) Underpins Outcomes in PHASE II (MAN) For personal use only 6
Slide 7: Why MPL for Cancer
Approved for Animal Health – For personal use only High Safety Margin Phase I (MAN) Showed Safety and Cancer Why MPL for Cancer Marker Activity Phase I (CANINE) Showed Safety and Cancer Marker Activity Extensive Preclinical Support (St George Hospital and GenScript) Encapsulation - Mechanism of Pala
Slide 8: High s6k Correlates with Multiple Negative Outcomes
High s6k Correlates with Multiple Negative Outcomes For personal use only Two complexes of mTOR (mammalian target of rapamycin) High s6k (p70s6k) in mTORC1 mTORC2 patients correlates with: PRAS40 Protor mSin1 mTOR mTOR Raptor GβL Rictor GβL Resistance to therapy Deptor Deptor Aggressive disease
Slide 9: Elevated p-RPS6KB1 is Associated with Poor Outcomes in Cancer
Elevated p-RPS6KB1(p70s6k) is Associated with Poor Outcomes in Cancer For personal use only High p-RPS6KB1 in patients with colorectal, lung, ovarian, pancreatic and hepatic cancers correlates with: • Resistance to therapy • Aggressive disease • Poor prognosis • High metastasis 1) Rapamune (Rapamyci
Slide 10: Suppression of p70s6k by MPL in Humans
Suppression of p70s6k by MPL in Humans For personal use only D e te r m in a tio n o f p -P 7 0 S 6 K in P B M C o f p a tie n ts tr e a te d w ith M P L D a y 1 b e fo re tre a tm e n t 100 D ay 3 ** * D ay 7 1 ** ** (% c o n tr o l) *** p -P 7 0 S 6 K 50 ****** **** 0 R 01 R 101 R 02 R 102 R 202 R
Slide 11: Suppression of p70s6k and tumour size and increased Quality of Life by MPL in Canines
Suppression of p70s6k and tumour size and increased Quality of Life by MPL in Canines For personal use only p-p70s6k P - p 7 0ELISA S 6 K E in li s dog 1oPBMC a in d g PBMC p-p70s6k ELISA in dog 2 PBMC P - p 7 0 S 6 K E lis a in d o g (M o r t im e r C a m b e ll) P B M C Relapsed Lymphoma Relapsed
Slide 12: Canine Cancer Trial
Canine Cancer Trial Department of Veterinary Medicine, University of Cambridge, UK For personal use only Aims: • Extend on Phase I canine cancer trial undertaken in Sydney which showed suppression of cancer marker p-Rps6kb1 • Demonstrate tumour regression or progression free survival • Outcome trigg
Slide 13: Effects of MPL in Canine Mammary Cancer
Effects of MPL in Canine Mammary Cancer For personal use only Pretreatment 1.9.16 4 Weeks 29.9.16 8 Weeks 27.10.16 Progressive Disease Progressive Disease Stable disease 13
Slide 14: Encapsulation
Major palatability drawback of MPL in human and Canine Trials being Resolved by Encapsulation For personal use only Compliance for more than 3 days of treatment in both man and canines was challenging in Phase I due to the remarkably foul taste of the MPL (Zolvix) liquid formulation manufactured by
Slide 15: In Summary: MPL Achieved Key Preclinical and Clinical Endpoints
In Summary MPL Achieved Key Preclinical and Clinical For personal use only Endpoints 1. Safety – Excellent safety profile as predicted from pre- clinical models 2. Active dose – Identified dosage of MPL from effects on cancer markers in man 3. Efficacy – Determined efficacy by markers and effects on
Slide 16: Potential for MPL Performance in Phase II (Man)
Potential for MPL Performance in Phase II (MAN) For personal use only Success in Phase II Canine Trials will Underpin Expectations in Phase II (MAN) Reformulation of MPL into Dry Powder in Capsule for Trial in MAN Exploratory Phase II Canine Trial will provide guidance on: Types of Cancer id
Slide 17: In Summary
In Summary Novartis Animal Health registered Zolvix (MPL) for the treatment of For personal use only parasitic diseases in animals Extensive manufacturing and toxicology already established by global major pharma company Over 50 MPL analogues are available for development and jointly owned wit
Slide 18: Experienced Management
Experienced Management For personal use only Dr. Roger Aston, Executive Chairman Dr Aston is both a scientist and seasoned biotechnology entrepreneur, with a successful track record in both fields. Previously at Wellcome Research Laboratories, Peptech, Cambridge Antibody Technology, QinetiQ, pSivida
Slide 19: Contact
For personal use only SAM WRIGHT DR ROGER ASTON Director & Company Secretary [email protected] Executive Chairman [email protected] ASX: PAA Phone: 61 (0) 408 900 277 Phone: 61 (0) 402 762 204 ACN 094 006 19 023